...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical drug investigation >An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19)
【24h】

An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19)

机译：羟氯喹对冠状病毒疾病-19（Covid-19）的更新系统综述

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and Objective The world is currently experiencing the Coronavirus Disease-19 (COVID-19) pandemic. There is no approved drug for the definitive treatment of the disease. Various drugs are being tried for the treatment of COVID-19, including hydroxychloroquine (HCQ). This study was performed to systematically review the therapeutic role of HCQ in COVID-19 from the available literature. Methods PubMed, Embase, ClinicalTrials.gov, ICTRP (WHO), Cochrane Library databases, and two pre-print servers (medRxiv.org and Research Square) were searched for clinical studies that evaluated the therapeutic role of HCQ on COVID-19 until 10 May 2020. The available studies were critically analyzed and the data were extracted. Results A total of 663 articles were screened and 12 clinical studies (seven peer-reviewed and published studies and five non-peer-reviewed studies from pre-print servers) with a total sample size of 3543 patients were included. Some of the clinical studies demonstrated good virological and clinical outcomes with HCQ alone or in combination with azithromycin in COVID-19 patients, although the studies had major methodological limitations. Some of the other studies showed negative results with HCQ therapy along with the risk of adverse reactions. Conclusion The results of efficacy and safety of HCQ in COVID-19, as obtained from the clinical studies, are not satisfactory, although many of these studies had major methodological limitations. Stronger evidence from well-designed robust randomized clinical trials is required before conclusively determining the role of HCQ in the treatment of COVID-19. Clinical prudence is required in advocating HCQ as a therapeutic armamentarium in COVID-19.
机译：背景和目标目前正在经历冠状病毒疾病-19（Covid-19）大流行。没有批准的药物用于对疾病的最终治疗。正在尝试治疗Covid-19的各种药物，包括羟氯喹（HCQ）。本研究进行了系统地检讨HCQ在可用文献中的HCQ在Covid-19中的治疗作用。方法PubMed，Embase，ClinicalTrials.gov，ICTRP（WHO），Cochrane图书馆数据库和两个预打印服务器（MEDRXIV.ORG和Research Square）被搜查参考临床研究，评估HCQ对Covid-19直到10的治疗作用2020年5月。可用的研究得到严重分析，提取数据。结果总共筛选了663篇文章，包括3543名患者的总样本大小的12项临床研究（来自预印刷服务器的七项同行评审和公布的研究和五项非同行评审研究）。一些临床研究表明，单独的HCQ或与Covid-19患者中的氮霉素组合良好的病毒学和临床结果，尽管研究具有主要的方法论限制。其他一些研究表明，HCQ治疗以及不良反应的风险显示出阴性结果。结论从临床研究中获得的Covid-19中HCQ疗效和安全性的结果并不令人满意，尽管这些研究中的许多研究具有主要的方法论限制。在结论HCQ在Covid-19治疗过程中，需要精心设计的稳健随机临床试验的更强的证据是必需的。在Covid-19中倡导HCQ作为治疗盔甲需要临床审慎。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号